Study on the application of nabuprofen in the early treatment of severe acute pancreatitis

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2300071143

Enrollment

Unknown

Registered

2023-05-06

Start date

2023-04-26

Completion date

Unknown

Last updated

2023-06-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Severe acute pancreatitis

Interventions

Experimental group:A nalbuphine analgesic and sedative regimen

Control group:Non naphthenic analgesic and sedative regimen

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) Conforming to the diagnosis of acute pancreatitis; (2) Evaluate the improved Mashall scoring system within 48 hours, with a score of = 2 points

Exclusion criteria

Exclusion criteria: (1) Visit and admission after 48 hours of onset (2) Complete obstructive biliary pancreatitis (requiring emergency surgical treatment) (3) Traumatic pancreatitis (4) Pregnancy with pancreatitis (5) Age80 years old (6) Previous basic diseases such as heart and lung (7) Have used nalbuphine for analgesic treatment within the past week

Design outcomes

Primary

Measure	Time frame
Analgesic evaluation comparison;	—

Secondary

Measure	Time frame
Impact on organ damage;ICU hospitalization time;Total hospitalization time;28 day mortality rate;hospital mortality;	—

Countries

China

Contacts

Public ContactSunYun

he Second Affiliated Hospital of Anhui Medical University

sunyun9653@126.com+86 13083400720

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026